
Study identifies new targets in the angiogenesis process
Research News Release
EurekAlert! provides eligible reporters with free access to embargoed and breaking news releases.
Eligibility GuidelinesEurekAlert! offers eligible public information officers paid access to a reliable news release distribution service.
Eligibility GuidelinesEurekAlert! is a service of the American Association for the Advancement of Science.
The study has demonstrated the involvement of a new Ca2+ ion entry pathway in angiogenesis processes and the formation of new blood vessels. This Ca2+ pathway is known as SOCE (store operated Ca2+ entry).
Researchers at Tokyo Medical and Dental University (TMDU) have developed an ingenious therapeutic strategy against chronic myelomonocytic leukemia that links a cytotoxic drug payload to an antibody vector that targets the CD64 marker highly expressed by monocytes and monocytic progenitors. This selective antibody-drug conjugate spares other blood cell lineages thus avoiding the side-effects of conventional anti-cancer drugs such as anemia, infection or bleeding diatheses. Consequently, this drug-delivery tactic shows great promise against other monocyte-related diseases.
Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer. According to researchers, these studies could help inform the ideal time for vaccination of these populations.
Researchers at Children's Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that two existing drug candidates--JAK inhibitors and Mepron--hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children. The foundational study, published in the journal Blood, is a first step toward finding effective treatments for the hard-to-treat blood cancer.
Bottom Line: The U.S. Preventive Services Task Force (USPSTF) concludes that the current evidence is insufficient to make a recommendation about screening for vitamin D deficiency in asymptomatic adults. Vitamin D performs an important role in bone metabolism. Requirements may vary by individual and no one blood vitamin D level defines deficiency.
A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15.
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA found using a bilateral attack achieves a more robust defense and helps avoid relapse.
Cycling at moderate intensity during dialysis could drastically improve the heart health of patients with kidney failure and result in significant savings for the NHS, according to new research by the University of Leicester supported by the charity Kidney Research UK and National Institute for Health Research (NIHR) Leicester Biomedical Research Centre.
This study investigated the role of droplet or contact transmission in the development of Kawasaki disease in Japan during the COVID-19 state of emergency. Kawasaki disease primarily affects children and is characterized by fever and swelling in the walls of some blood vessels.